HK1089356A1 - Synergistic combinations comprising a renin inhibitor for cardiovascular diseases - Google Patents

Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Info

Publication number
HK1089356A1
HK1089356A1 HK06106355A HK06106355A HK1089356A1 HK 1089356 A1 HK1089356 A1 HK 1089356A1 HK 06106355 A HK06106355 A HK 06106355A HK 06106355 A HK06106355 A HK 06106355A HK 1089356 A1 HK1089356 A1 HK 1089356A1
Authority
HK
Hong Kong
Prior art keywords
renin inhibitor
cardiovascular diseases
synergistic combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HK06106355A
Other languages
English (en)
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Weeb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1089356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1089356A1 publication Critical patent/HK1089356A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
HK06106355A 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases HK1089356A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
HK04100924A HK1059212A1 (en) 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (1)

Publication Number Publication Date
HK1089356A1 true HK1089356A1 (en) 2006-12-01

Family

ID=9903412

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06106355A HK1089356A1 (en) 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK04100924A HK1059212A1 (en) 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK08107208A HK1115544A1 (en) 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK04100924A HK1059212A1 (en) 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
HK08107208A HK1115544A1 (en) 2000-11-17 2004-02-11 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Country Status (32)

Country Link
US (4) US8168616B1 (ja)
EP (7) EP1915993B1 (ja)
JP (6) JP2004513920A (ja)
KR (6) KR101258365B1 (ja)
CN (4) CN101264073A (ja)
AT (2) ATE317692T1 (ja)
AU (2) AU2002223680B2 (ja)
BR (1) BR0115411A (ja)
CA (2) CA2763223A1 (ja)
CY (5) CY1105603T1 (ja)
CZ (2) CZ305341B6 (ja)
DE (3) DE60134349D1 (ja)
DK (3) DK1341533T3 (ja)
EC (1) ECSP034603A (ja)
ES (4) ES2308347T3 (ja)
GB (1) GB0028151D0 (ja)
HK (3) HK1089356A1 (ja)
HU (2) HU230882B1 (ja)
IL (3) IL155707A (ja)
LU (2) LU91563I2 (ja)
MX (1) MXPA03004358A (ja)
NL (2) NL300385I1 (ja)
NO (2) NO334002B1 (ja)
NZ (6) NZ537691A (ja)
PL (3) PL400914A1 (ja)
PT (3) PT1341533E (ja)
RU (2) RU2310443C2 (ja)
SG (1) SG135969A1 (ja)
SI (3) SI1341533T1 (ja)
SK (1) SK287881B6 (ja)
WO (1) WO2002040007A1 (ja)
ZA (1) ZA200303497B (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213357A (pt) * 2001-10-18 2004-10-26 Novartis Ag Compostos orgânicos
US20050182042A1 (en) * 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
AU2003250858A1 (en) * 2002-06-28 2004-01-19 Novartis Ag Use of organic compounds
AU2003255527A1 (en) * 2002-06-28 2004-01-19 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
RU2413716C2 (ru) * 2003-11-26 2011-03-10 Новартис Аг АМИДЫ δ-АМИНО-γ-ГИДРОКСИ-ω-АРИЛАЛКАНОВОЙ КИСЛОТЫ
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
WO2005070871A2 (en) * 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
US7767690B2 (en) 2004-01-23 2010-08-03 Novartis Ag Amino alcohol derivatives and their use as renin inhibitor
WO2005070877A1 (en) * 2004-01-23 2005-08-04 Speedel Experimenta Ag Diamino alcohols and their use as renin inhibitors
BRPI0508880A (pt) * 2004-03-17 2007-09-04 Novartis Ag uso de compostos orgánicos
MY148773A (en) 2004-03-17 2013-05-31 Novartis Ag Galenic formulations of organic compounds
CN1934082A (zh) * 2004-03-19 2007-03-21 斯皮德尔实验股份公司 有机化合物
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
JP2008515903A (ja) * 2004-10-08 2008-05-15 ノバルティス アクチエンゲゼルシャフト 拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
RU2007143503A (ru) * 2005-04-27 2009-06-10 Новартис АГ (CH) Способы лечения атеросклероза
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
EP1932528A1 (en) * 2005-09-28 2008-06-18 Teva Pharmaceutical Industries Ltd Stable composition of amlodipine besylate
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US20080261958A1 (en) * 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
MX2009006340A (es) * 2006-12-15 2009-06-23 Novartis Ag Metodos terapeuticos.
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
TW200924737A (en) * 2007-09-28 2009-06-16 Novartis Ag Galenical formulations of organic compounds
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
KR101164300B1 (ko) 2008-02-22 2012-07-09 한올바이오파마주식회사 약제학적 제제
US20110111022A1 (en) 2008-04-10 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
CN102065847A (zh) 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
RU2011142081A (ru) 2009-03-20 2013-04-27 Новартис Аг Галеновые фиксированные комбинации валсартана и алискирена
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
WO2012152718A1 (en) 2011-05-06 2012-11-15 Farmicom Pharmaceutical Company D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
AU2013262438B2 (en) * 2012-05-18 2017-03-16 Luoda Pharma Limited Liquid formulation
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
KR20170038021A (ko) 2014-07-30 2017-04-05 메르크 파텐트 게엠베하 직접 압축성 폴리비닐 알코올
MX2019004937A (es) * 2016-10-27 2019-06-24 Damian Pharma Ag Inhibidor de aldosterona sintasa.

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022978A1 (en) 1995-01-27 1996-08-01 Rhone Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
CA2018438C (en) 1989-06-14 2000-08-08 Joseph Alan Finkelstein Imidazolyl-alkenoic acids
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
JPH06500111A (ja) * 1990-08-15 1994-01-06 アボツト・ラボラトリーズ レニン阻害剤
AU656551B2 (en) 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (ja) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
NZ266314A (en) 1993-04-27 1998-10-28 Smithkline Beecham Corp Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
AU675870B2 (en) 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
ATE219077T1 (de) 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (ja) 1994-12-20 1997-08-21 Hoffmann La Roche
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997022595A1 (fr) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Derives arylethenesulfonamide et composition de medicaments renfermant ces derives
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
AU1319697A (en) 1996-01-23 1997-08-20 Shionogi & Co., Ltd. Process for producing oleanolic acid analogs by culturing hairy root
ES2241047T3 (es) 1996-04-04 2005-10-16 Banyu Pharmaceutical Co., Ltd. Antagonistas de la endotelina para tratar la insuficiencia cardiaca.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
BR9912145A (pt) 1998-07-20 2001-09-25 Smithkline Beecham Corp Formulações bioaperfeiçoadas contendo eprosartan em forma de dosagem sólida oral
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CA2368187A1 (en) * 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
ATE370738T1 (de) 1999-11-09 2007-09-15 Pharmacia Corp Verwendung von eplerenon zur behandlung von restenose
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
US20050182042A1 (en) 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
DE60134349D1 (de) 2008-07-17
CA2428647A1 (en) 2002-05-23
WO2002040007A1 (en) 2002-05-23
RU2346703C2 (ru) 2009-02-20
CY2013045I1 (el) 2015-11-04
ES2734523T3 (es) 2019-12-10
SI1915993T1 (sl) 2013-10-30
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
IL212075A0 (en) 2011-06-30
EP1602370A3 (en) 2005-12-14
HUP0301841A3 (en) 2010-07-28
CN1474690A (zh) 2004-02-11
NZ550898A (en) 2008-07-31
EP1341533A1 (en) 2003-09-10
NO20032233L (no) 2003-05-16
EP2305233A1 (en) 2011-04-06
ATE317692T1 (de) 2006-03-15
CY2009005I2 (el) 2012-01-25
IL155707A0 (en) 2003-11-23
DK1915993T3 (da) 2013-10-14
SG135969A1 (en) 2007-10-29
HU1400409D0 (hu) 2003-09-29
NO2013019I2 (no) 2013-12-17
NO2013019I1 (no) 2014-06-02
DK1602370T3 (da) 2008-09-22
CY2009005I1 (el) 2012-01-25
CN100404024C (zh) 2008-07-23
CN101264073A (zh) 2008-09-17
NL300385I1 (nl) 2009-07-01
NZ537691A (en) 2007-01-26
ES2256335T3 (es) 2006-07-16
RU2310443C2 (ru) 2007-11-20
KR101008752B1 (ko) 2011-01-14
EP1915993A1 (en) 2008-04-30
ES2429292T3 (es) 2013-11-14
ATE397445T1 (de) 2008-06-15
MXPA03004358A (es) 2003-08-19
JP6373931B2 (ja) 2018-08-15
CY2013045I2 (el) 2015-11-04
PL227576B1 (pl) 2017-12-29
PT1602370E (pt) 2008-09-10
HU230882B1 (hu) 2018-11-29
NZ550897A (en) 2008-03-28
ES2308347T3 (es) 2008-12-01
DE122009000021I1 (de) 2009-08-06
EP1602370B1 (en) 2008-06-04
NZ568764A (en) 2009-11-27
US9023893B2 (en) 2015-05-05
LU92315I2 (fr) 2014-01-27
EP1915993B1 (en) 2013-07-10
CY1108305T1 (el) 2012-01-25
US20120004312A1 (en) 2012-01-05
EP2305232B1 (en) 2019-07-17
PL400914A1 (pl) 2012-12-17
EP1602370A2 (en) 2005-12-07
JP2004513920A (ja) 2004-05-13
ECSP034603A (es) 2003-06-25
NO20032233D0 (no) 2003-05-16
AU2002223680B2 (en) 2005-04-07
CZ299749B6 (cs) 2008-11-12
HK1059212A1 (en) 2004-06-25
US20120010295A1 (en) 2012-01-12
SK5842003A3 (en) 2003-11-04
KR20100114904A (ko) 2010-10-26
HUP0301841A2 (hu) 2003-09-29
HK1115544A1 (en) 2008-12-05
SI1602370T1 (sl) 2008-10-31
CY1114829T1 (el) 2015-11-04
US9023894B2 (en) 2015-05-05
EP2305231A1 (en) 2011-04-06
NZ525795A (en) 2005-03-24
SI1341533T1 (sl) 2006-08-31
CZ305341B6 (cs) 2015-08-05
LU91563I2 (fr) 2009-07-06
KR20080096715A (ko) 2008-10-31
SK287881B6 (sk) 2012-02-03
US20120016035A1 (en) 2012-01-19
NO334002B1 (no) 2013-11-11
KR20110063596A (ko) 2011-06-10
EP2305232A1 (en) 2011-04-06
PL400915A1 (pl) 2012-12-17
JP6089278B2 (ja) 2017-03-08
EP1341533B1 (en) 2006-02-15
IL212075A (en) 2013-08-29
DE60117295T2 (de) 2006-08-17
NL301005I1 (ja) 2019-09-10
KR20030051753A (ko) 2003-06-25
JP2018131465A (ja) 2018-08-23
JP2009235107A (ja) 2009-10-15
CN101264072A (zh) 2008-09-17
JP6603757B2 (ja) 2019-11-06
RU2006132668A (ru) 2008-03-20
CY1105603T1 (el) 2010-07-28
GB0028151D0 (en) 2001-01-03
NL301005I2 (nl) 2019-10-29
CA2763223A1 (en) 2002-05-23
DK1341533T3 (da) 2006-05-08
KR20080011355A (ko) 2008-02-01
DE60117295D1 (de) 2006-04-20
KR101258365B1 (ko) 2013-04-30
AU2368002A (en) 2002-05-27
JP2017019876A (ja) 2017-01-26
US8618174B2 (en) 2013-12-31
US8168616B1 (en) 2012-05-01
BR0115411A (pt) 2004-08-17
IL217847A0 (en) 2012-03-29
ZA200303497B (en) 2004-04-28
EP1930000A1 (en) 2008-06-11
JP2018030894A (ja) 2018-03-01
PL361404A1 (en) 2004-10-04
PT1341533E (pt) 2006-06-30
IL155707A (en) 2012-02-29
JP6577994B2 (ja) 2019-09-18
CN101091703A (zh) 2007-12-26
KR20080097488A (ko) 2008-11-05
JP2013213061A (ja) 2013-10-17

Similar Documents

Publication Publication Date Title
NL301005I1 (ja)
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
GB9410898D0 (en) Pharmaceutical compositions having analgesic activity
GB9907571D0 (en) Compounds
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
EP0978287A4 (en) MEDICAL COMPOSITION CONTAINING AS GP34 INHIBITOR BINDING INHIBITOR.
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
IL127227A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis
IL121488A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161115